| Print
NICOX (ALCOX)
NICOX S.A.This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, withGlaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.
Address
Les Taissounières
1681 Route des Dolines
Sophia Antipolis
FRA
06 906
Telephone
+33 497245300
Forecast key dates
| Name | Key Date |
|---|
Previous key dates
| Name | Key Date |
|---|---|
| Nicox SA Second Quarter Earnings Results for 2024 | 2024-07-19T00:00:00 |
| Nicox SA Annual Report for 2023 | 2024-06-06T00:00:00 |
| Nicox SA First Quarter Earnings Results for 2024 | 2024-05-31T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.